Abstract
Description/Summary
Many diseases such as cardiovascular disorders, diabetes or neurodegenerative
diseases are the consequences of dysfunction of specific cells. Strategies
were developed to repair or regenerate the damaged tissues using
differentiated cells out of stem cells. However, ethical and scientific issues
are related to the use of embryonic stem cells. In this context, induced
pluripotent stem cells (iPS) appear as a promising approach. The patient's
somatic cells are first dedifferentiated into iPS cells and then
redifferentiated into the cell of interest. This revolutionary technology
represents major scientific, societal and economic challenges and was recently
rewarded by a Nobel Prize in Physiology and Medicine to Prof. Shinya Yamanaka
and Prof. John Gurdon.
With over 1000 patent families qualified and analyzed out of a pool of 3000
patent families, we have analysed:
The "iPS cells generation" patent landscape
The analysis of this patent landscape shows a strong complexity of the
environment and demonstrates the ability of institutional players to develop a
consistent IP strategy like the one from Kyoto university. Some major players
already present in 2011 increased sharply their filings: the Kyoto university,
the Chinese Academy of Sciences, the laboratories of US government. New
entrants have filed numerous patent applications in the last years: Korea
university, AIST, Cellular Dynamics, Salk Institute and A*STAR (SG).
The "iPS cells differentiation" patent landscape
As for the thematic "iPS cells generation", the main players are mainly
institutional (23 institutional applicants in the top 30) with the university
of Kyoto and the laboratories of the US government at the first two places.
However, industrial applicants from all over the world clearly positioned
themselves on the thematic such as Cellular Dynamics (US), Cellectis (FR) or
Viacyte (US). The technological breakdowns presented in this study had shown
specific positioning of the players through their patent applications notably
regarding the type of cell obtained from the differentiation of iPS cells.
Cardiovascular, neural, pancreatic cells are the most claimed by the
applicants, this corresponding to the main pathologies observed nowadays.
Hepatic cells are also often claimed notably for the establishment of
toxicology studies.
The "iPS cells database"
Additionally, all patents dealing with iPS cells but who were concerning
neither generation nor differentiation (thus all patents related to culture,
selection, isolation, etc...) were grouped together in a database to get a
full overview of the iPS landscape.
These patent landscapes provide you a comprehensive panorama of the
intellectual property overview and help you:
- Identify key inventors and players involved in the generation and
differentiation of iPS cells
- Understand their positioning, the collaboration networks and their dynamics
- Analyze their IP strategy
- Position your company's R&D and IP portfolio
- Discover new trends and emerging topics
Table of Contents
Overview
Generalities
- Brief outline of the technology: generation and source of stem cells
- Brief outline of the technology: reprogramming techniques
- Global search strategy of patents and patent applications related to iPS
cells
Evolution and location of patent filings
- Evolution of patent filings (1999-2013)
- Map and evolution of priority filings
- Map of extensions
Analysis of patent applicants
- Main applicants on the entire period (1999-2013)
- Part of the portfolio hold by the first 10 applicants
- Breakdown of filings of the main institutional/industrial applicants over
time
- Main co-filings between applicants
- Applicants and their affiliates
Analysis of inventors
- List of the main inventors
- Main research teams
Breakdown of the patent portfolio
Breakdown of the portfolio (for each breakdown are presented the distribution
of technologies, the evolution of fillings and the positioning of
institutional applicants, industrial applicants and inventors)
Breakdown of the portfolio
- 1 Origin of cell to be reprogrammed
- 2 Type of cell to be reprogrammed
- 3 iPS cells generation technique
- 4 Type of reprogramming factor 1
- 5 Type of reprogramming factor 2
- 6 Method of delivery
Citation, extension & granted analysis
- List of most cited patents and patent applications
- List of the most extended patents & patent applications
- Granted and not granted patents filed by institutional/industrial
applicants by office
Applicant focuses
- Kyoto university
- Chinese Academy of Sciences
- US government
- Harvard university
- Korea university
- Cellular dynamics
- Whitehead biomedical institute
- Advanced Industrial Science and Technology
- California university
Conclusive comments
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
